BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 18376365)

  • 1. Sorafenib, a systemic therapy for hepatocellular carcinoma.
    Méndez-Sánchez N; Vásquez-Fernández F; Zamora-Valdés D; Uribe M
    Ann Hepatol; 2008; 7(1):46-51. PubMed ID: 18376365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
    Zhu AX
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():1-2. PubMed ID: 22873622
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
    Abou-Alfa GK
    Oncologist; 2009 Jan; 14(1):92-4. PubMed ID: 19144679
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatocellular carcinoma: sorafenib before liver transplantation?
    Braillon A
    Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
    Rowe IA
    Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib for HCC: a pragmatic perspective.
    Razumilava N; Gores GJ
    Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
    [No Abstract]   [Full Text] [Related]  

  • 8. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
    Zhu AX; Clark JW
    Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
    [No Abstract]   [Full Text] [Related]  

  • 9. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
    Ranieri G; Gadaleta-Caldarola G; Goffredo V; Patruno R; Mangia A; Rizzo A; Sciorsci RL; Gadaleta CD
    Curr Med Chem; 2012; 19(7):938-44. PubMed ID: 22214462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib for liver cancer: the horizon broadens.
    Johnson P; Billingham L
    Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
    [No Abstract]   [Full Text] [Related]  

  • 12. Selection of patients with hepatocellular carcinoma for sorafenib.
    Abou-Alfa GK
    J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life and sorafenib.
    Spinzi G; Terreni N
    Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
    [No Abstract]   [Full Text] [Related]  

  • 14. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
    Burak KW
    Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
    [No Abstract]   [Full Text] [Related]  

  • 15. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
    World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R; Byrne MT; Tan A; Aucejo F
    Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
    Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
    Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
    Pazo Cid RA; Lao J; Lanzuela M
    JAMA; 2011 Feb; 305(8):781; author reply 781. PubMed ID: 21343576
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hepatocellular carcinoma].
    Yamashita T; Arai K; Kaneko S
    Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.